TruScreen's clinical performance
The TruScreen device has been clinically validated by over 30 published trials involving more than 40,000 women, using an objective digital system to avoid subjective human judgment in cervical screening.
truscreen.comCrawled Nov 19, 2026
The TruScreen device has been clinically validated by over 30 published trials involving more than 40,000 women, using an objective digital system to avoid subjective human judgment in cervical screening.
TruScreen partnered with Dalton Bioscience, a leading China based manufacturer of high-performance HPV DNA tests and laboratory equipment for cervical cancer screening, to distribute complementary HPV-related In Vitro Diagnostics (“IVD”) products through TruScreen’s global distribution network.
The WHO aims for a 70% cervical screening rate by age 35 using high-performance tests, with TruScreen’s technology suited to support emerging economies lacking screening infrastructure.
TruScreen offers a digital alternative to traditional cervical screening methods, addressing issues like failed samples, poor follow-up, patient discomfort, and the need for laboratory infrastructure.
TruScreen has screened over 1 million women across 20 countries, trained over 1,000 healthcare professionals in 230 hospitals or clinics, and operates over 250 devices globally.
The August issue of TruScreen’s newsletter - Beyond Screening.
The October issue of TruScreen’s newsletter - Beyond Screening.
Recognizing the early warning signs of cervical cancer is critical for timely diagnosis and treatment. Although early stage cervical cancer frequently occurs without symptoms, awareness of the signs can help enable early detection and treatment to improve outcomes.
A young Auckland real estate agent is battling stage 3 cervical cancer after a misread smear test delayed her diagnosis by a year. Such stories highlight the inherent risk of using ageing methodologies with subjective human interpretation to screen for cervical cancer.
Public health reports show older women in rural or low-resource settings in China and Asia often lack access to cervical screening programs, increasing their risk of advanced-stage cervical cancer.
TruScreen publishes market announcements, clinical updates, and reports to inform stakeholders about progress toward eliminating cervical cancer.
TruScreen has now finalised the Renounceable Rights Issue and shortfall bookbuild, which was substantially oversubscribed. This brings the total amount of the Placement and Rights Issue capital raise to just over NZ$4 million.
Distributors are appointed for Nigeria, Ghana, Cote D’Ivoire and Rwanda – launching the Company’s African expansion and supporting government initiatives to meet World Health Organisation screening targets through public screening programs.
TruScreen’s Dr Carolina Velasquez and Ms Sumaya Mozumder presented the product to the Bangladesh Ministry of Health, NICRH, and DocTime, with support from local distributor Xerox Medica Ltd.
TruScreen Group Limited (NZX: TRU) has released its Annual Report for the year ended 31 March 2026.
TruScreen Ultra has received product registration in Kenya, where cervical cancer is the leading cause of cancer death among women, with only 6% screened. Distributor Ansell Pharmaceuticals supports entry into a market of over 17 million women.
The page introduces TruScreen’s leadership team, including its board, management, medical advisory committee, and international experts group.
The TruScreen device combines over two decades of work by scientists, engineers, and clinicians, alongside CSIRO and the University of Sydney, to develop its Ultra classifier algorithm.
View TruScreen's past financial reports here.
TruScreen Group Limited is listed on the NZX and ASX under the ticker TRU. The page provides shareholder and investor information, financial reports, and corporate governance documentation.
View TruScreen's Corporate Governance documentation here.
TruScreen Group Limited (NZX/ASX: TRU) is a New Zealand and Australian listed medical device company that has developed an AI-enabled device that can detect precancerous and cancerous cervical changes in real-time via optical and electrical measurements of cervical tissue.
TruScreen Group Limited (NZX/ASX: TRU) is a New Zealand and Australian listed medical device company that has developed an AI-enabled device that can detect precancerous and cancerous cervical changes in real-time via optical and electrical measurements of cervical tissue.